Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Zen Rating | Price | Value | Graham Fair Value | Graham Fair Value % | P/E | Forward P/E | P/S | P/B | PEG | Free Cash Flow | Free Cash Flow Yield | Book Value | BVPS | EV | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LQDA | LIQUIDIA CORP | $55.69 | $18.58 | 199.73% | 232.04x | 16.80x | 17.01x | 45.61x | 1.10x | $41.15M | 0.84% | $108.58M | 1.23 | $4.91B | 91.68 | ||
| CORT | CORCEPT THERAPEUTICS INC | $72.65 | $19.15 | 279.35% | 157.93x | 138.75x | 9.87x | 12.22x | 1.49x | $119.79M | 1.58% | $637.99M | 6.11 | $7.70B | -1,121.47 | ||
| XERS | XERIS BIOPHARMA HOLDINGS INC | $5.89 | $2.87 | 105.21% | 84.14x | 49.29x | 3.19x | 78.15x | 0.81x | $47.52M | 4.74% | $13.01M | 0.08 | $1.16B | 21.78 | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $292.58 | $95.75 | 205.58% | 67.11x | 39.67x | 9.07x | 36.32x | 1.38x | $641.34M | 1.65% | $1.08B | 8.09 | $40.32B | 43.62 | ||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $47.85 | $17.60 | 171.82% | 48.83x | 37.48x | 4.86x | 6.08x | 1.32x | $164.23M | 4.48% | $605.69M | 7.92 | $3.50B | 31.40 | ||
| KRYS | KRYSTAL BIOTECH INC | $301.82 | $97.22 | 210.46% | 38.94x | 37.33x | 21.18x | 6.97x | 1.85x | $237.38M | 2.69% | $1.28B | 43.59 | $8.41B | 39.29 | ||
| ADMA | ADMA BIOLOGICS INC | $7.76 | $10.66 | -27.18% | 11.25x | 7.82x | 3.59x | 4.61x | 0.38x | $107.90M | 5.89% | $390.33M | 1.65 | $1.86B | 8.39 | ||
| OMER | OMEROS CORP | $10.16 | $15.78 | -35.61% | 7.82x | -26.68x | 73.62x | -11.61x | 0.39x | -$94.78M | -12.97% | -$63.33M | -0.88 | $1.04B | 11.55 | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $54.66 | $41.50 | 31.71% | 39.04x | 13.76x | 3.25x | 1.70x | 0.55x | $767.06M | 7.29% | $6.21B | 32.27 | $8.92B | 18.49 | ||
| RPRX | ROYALTY PHARMA PLC | $54.97 | $40.53 | 35.62% | 28.78x | 10.31x | 9.84x | 3.19x | 0.62x | $2.34B | 9.75% | $9.94B | 22.75 | $40.02B | 34.40 | ||
| ZVRA | ZEVRA THERAPEUTICS INC | $10.96 | $16.53 | -33.68% | 5.35x | 23.32x | 5.23x | 3.15x | 0.67x | $56.42M | 8.81% | $205.80M | 3.52 | $553.45M | 3.83 | ||
| HALO | HALOZYME THERAPEUTICS INC | $69.82 | $71.66 | -2.57% | 23.59x | 8.43x | 5.47x | 37.71x | 0.43x | $667.65M | 8.09% | $219.64M | 1.86 | $10.11B | 16.21 | ||
| VCEL | VERICEL CORP | $34.74 | $9.29 | 274.14% | 80.79x | 72.06x | 6.04x | 4.98x | 1.70x | $47.49M | 2.69% | $356.23M | 7.02 | $1.76B | 43.53 | ||
| LGND | LIGAND PHARMACEUTICALS INC | $234.40 | $97.25 | 141.03% | 29.67x | 26.01x | 16.98x | 4.71x | 1.46x | $122.22M | 2.62% | $997.32M | 50.16 | $5.03B | 22.32 | ||
| ASND | ASCENDIS PHARMA A | $216.79 | $85.14 | 154.63% | 22.98x | 17.46x | 13.22x | 23.45x | 2.14x | $52.94M | 0.39% | $574.09M | 9.24 | $13.85B | 148.48 | ||
| JAZZ | JAZZ PHARMACEUTICALS PLC | $230.93 | $49.54 | 366.13% | 491.34x | 8.94x | 3.22x | 3.20x | 1.68x | $1.30B | 9.08% | $4.53B | 73.22 | $18.05B | 26.73 | ||
| SPRO | SPERO THERAPEUTICS INC | $2.80 | $5.83 | -51.96% | 10.37x | 4.10x | 2.62x | 3.06x | 0.22x | $7.24M | 4.50% | $52.93M | 0.92 | $108.47M | 7.00 | ||
| TECH | BIO-TECHNE CORP | $50.85 | $15.64 | 225.18% | 71.62x | 25.86x | 6.57x | 3.82x | 1.47x | $269.60M | 3.39% | $2.09B | 13.34 | $8.04B | 31.42 | ||
| TGTX | TG THERAPEUTICS INC | $40.11 | $18.92 | 111.95% | 12.46x | 26.72x | 8.27x | 10.53x | 8.15x | -$14.19M | -0.24% | $583.13M | 4.04 | $6.45B | 42.99 | ||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $32.10 | $36.44 | -11.91% | 12.69x | 8.74x | 2.06x | 2.04x | 0.48x | $341.79M | 18.41% | $910.35M | 15.75 | $1.43B | 6.03 | ||
| UTHR | UNITED THERAPEUTICS CORP | $549.47 | $251.38 | 118.58% | 18.77x | 18.90x | 7.54x | 3.95x | 1.98x | $1.02B | 4.25% | $5.90B | 135.66 | $22.04B | 12.86 | ||
| VRTX | VERTEX PHARMACEUTICALS INC | $428.34 | $172.50 | 148.31% | 25.18x | 21.89x | 8.91x | 5.61x | 1.80x | $3.71B | 3.41% | $19.36B | 76.20 | $105.21B | 19.51 | ||
| NAGE | NIAGEN BIOSCIENCE INC | $3.44 | $2.50 | 37.62% | 14.33x | 14.54x | 2.11x | 3.33x | 0.97x | $4.11M | 1.48% | $82.33M | 1.03 | $210.00M | 9.89 | ||
| EXEL | EXELIXIS INC | $51.60 | $31.35 | 64.61% | 16.54x | 15.66x | 5.61x | 6.70x | 1.20x | $917.69M | 6.88% | $1.94B | 7.49 | $12.91B | 12.23 | ||
| CPRX | CATALYST PHARMACEUTICALS INC | $31.28 | $15.14 | 106.59% | 17.28x | 16.26x | 6.41x | 3.78x | 1.96x | $208.13M | 5.44% | $1.01B | 8.28 | $3.07B | 9.18 | ||
| PLX | PROTALIX BIOTHERAPEUTICS INC | $1.96 | $1.77 | 10.74% | 10.32x | 9.02x | 2.05x | 2.35x | 0.89x | $13.00M | 8.32% | $67.23M | 0.84 | $124.69M | 5.58 | ||
| REGN | REGENERON PHARMACEUTICALS INC | $618.95 | $450.09 | 37.52% | 14.54x | 13.09x | 4.31x | 2.07x | 0.95x | $4.11B | 6.39% | $31.42B | 302.15 | $64.63B | 11.25 | ||
| VCYT | VERACYTE INC | $48.69 | $12.54 | 288.29% | 43.86x | 43.26x | 7.15x | 2.89x | 2.52x | $155.34M | 4.01% | $1.34B | 16.90 | $3.66B | 31.81 | ||
| SRPT | SAREPTA THERAPEUTICS INC | $16.24 | $4.68 | 247.34% | 27.07x | 4.66x | 0.78x | 1.14x | 3.79x | $109.24M | 6.40% | $1.51B | 14.34 | $2.29B | 27.64 | ||
| INCY | INCYTE CORP | $97.98 | $67.22 | 45.76% | 13.44x | 12.44x | 3.64x | 3.48x | 1.19x | $1.45B | 7.43% | $5.62B | 28.21 | $16.15B | 8.63 | ||
| MDXG | MIMEDX GROUP INC | $3.61 | $1.59 | 127.48% | 17.19x | -50.56x | 1.38x | 2.21x | 2.67x | $69.36M | 12.94% | $242.94M | 1.64 | $395.52M | 7.26 |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.